RecruitingACTRN12605000343606
Nitric Oxide Laboratory Animal Allergy Study
Use of serial exhaled nitric oxide measurements in detecting airways inflammation in subjects exposed to laboratory animals during a typical working week
Sponsor
ACC New Zealand
Enrollment
50 participants
Start Date
Feb 6, 2005
Study Type
Observational
Conditions
Eligibility
Sex: Both males and females
Plain Language Summary
Simplified for easier understanding
This study is looking at whether working regularly with laboratory animals causes airway inflammation that can be detected by measuring a gas in the breath called nitric oxide. People who work with animals in laboratories may develop allergies over time, and this study aims to find an early, non-invasive way to detect these allergic changes before they cause symptoms.
You may be eligible if:
- You work with laboratory animals at least 2 days per week
- You have been doing this work for at least 6 months
You may NOT be eligible if:
- You have taken oral or inhaled steroids in the last 6 weeks
Talk to your doctor about whether this trial might be right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
None
None
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000343606
Related Trials
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665135 locations
Personalized Environment and Genes Study
NCT003412371 location
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
NCT073996659 locations
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
NCT069811693 locations
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589143 locations